TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02109133
Drug: Atracurium
Normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02109133
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01737177
Drug: Bendamustine, Lenalidomide, Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days
Study: NCT03967483
Drug: Indometacin
Normalized name: Indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient who are taken indomatacin for headaches and migraine
Study: NCT00519012
Drug: Sertraline to Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
Study: NCT00519012
Drug: Paroxetine to Sertraline
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
Study: NCT02468557
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered orally twice daily
Study: NCT02468557
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
Study: NCT00526695
Drug: Sevoflurane (Preconditioning)
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of sub-anesthetic doses of sevoflurane
Study: NCT04098081
Drug: galeterone
Normalized name: Galeterone
DrugBank: Galeterone (DB12415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic
Study: NCT04098081
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Therapeutic
Study: NCT04357873
Drug: pembrolizumab; vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression
Study: NCT03247296
Drug: Sofosbuvir 400 mg, Daclatasvir, Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No intervention made this is an observational study to monitor the already existing protocols of the facility
Study: NCT04524299
Drug: Concurrent chemotherapy twice a week
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy
Study: NCT04524299
Drug: Concurrent chemotherapy once a week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
Study: NCT01393990
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01393990
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02123056
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study: NCT01750567
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
Study: NCT00275028
Drug: cediranib maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03543683
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
Study: NCT03543683
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study: NCT02688140
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02688140
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02688140
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02688140
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01976390
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.75mg twice a day, Orally, starting on day of transplant
Study: NCT01976390
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg, Orally, starting on day of transplant; decreasing to 3mg
Study: NCT05164549
Drug: Buprenorphine Injectable Product
Normalized name: buprenorphine Injectable Product
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigational Medicinal Product
Study: NCT05164549
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT05164549
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of Care
Study: NCT03827213
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A shot of long acting local anesthetic for post operative pain management
Study: NCT00830674
Drug: KRN23
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
Study: NCT00331630
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00331630
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04352413
Drug: PLM60
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration: Intravenous infusion
Study: NCT00916890
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
Study: NCT00916890
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
Study: NCT00916890
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
Study: NCT01193621
Drug: haloperidol, PET
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days.
Study: NCT03811379
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
Study: NCT03895099
Drug: Desogestrel early follicular phase
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start of ovarian stimulation in early follicular phase
Study: NCT03895099
Drug: Desogestrel medium follicular phase
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start of ovarian stimulation in medium follicular phase
Study: NCT03895099
Drug: Desogestrel ovulatory phase
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start of ovarian stimulation in ate follicular phase
Study: NCT03895099
Drug: Desogestrel late follicular phase
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start of ovarian stimulation in ovulatory Phase
Study: NCT03895099
Drug: Desogestrel luteal phase
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start of ovarian stimulation in luteal phase
Study: NCT02257359
Drug: Epelsiban
Normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
Study: NCT03248856
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic administration
Study: NCT01199328
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81mg Tablet oral, once daily
Study: NCT01199328
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Tablet oral, once daily
Study: NCT01033721
Drug: Palomid 529
Normalized name: Palomid 529
DrugBank: Palomid 529 (DB12812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT00720798
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
Study: NCT05461820
Drug: Methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
Study: NCT00005093
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005093
Drug: tacedinaline
Normalized name: Tacedinaline
DrugBank: Tacedinaline (DB12291)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00096083
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02291536
Drug: tetrahydrocannabinol
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02291536
Drug: cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01438723
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
Study: NCT00470847
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally twice daily
Study: NCT00470847
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
Study: NCT01268150
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
Study: NCT04469075
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
Study: NCT03083210
Drug: Lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
Study: NCT01104155
Drug: eribulin mesylate + erlotinib
Normalized name: Eribulin Mesylate
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
Study: NCT01104155
Drug: eribulin mesylate + erlotinib
Normalized name: Eribulin Mesylate
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
Study: NCT01953588
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg IM
Study: NCT01953588
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole 1 mg oral tablet
Study: NCT00975637
Drug: 70 mg SC
Normalized name: lofepramine 70 MG
DrugBank: Lofepramine (DB13411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg SC
Study: NCT00975637
Drug: 210 mg SC
Normalized name: aspirin 210 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 210 mg SC
Study: NCT00975637
Drug: 140 mg SC
Normalized name: trenbolone 140 MG
DrugBank: Trenbolone (DB11551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg SC
Study: NCT00975637
Drug: 280 mg SC
Normalized name: ibrutinib 280 MG
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 280 mg SC
Study: NCT02700022
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
Study: NCT01704664
Drug: glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
Study: NCT01704664
Drug: Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
Study: NCT00452478
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
Study: NCT00198497
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase 55 IU in saline solution
Study: NCT00198497
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase 75 IU in saline solution
Study: NCT02036281
Drug: Substance P-Saporin
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03308448
Drug: Recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
Study: NCT00532155
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
Study: NCT00532155
Drug: Docetaxel (Taxotere®)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
Study: NCT00532155
Drug: Dexamethasone (pre- and post-medication for docetaxel)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
Study: NCT01924624
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period